{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:50:44Z","timestamp":1794073844011,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.mehy.2016.07.016","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T07:30:51Z","timestamp":1469604651000},"page":"151-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy"],"prefix":"10.1016","volume":"94","author":[{"given":"Mehmet Gokhan","family":"Culha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Cagkan","family":"Inkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ege Can","family":"Serefoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2016.07.016_b0005","series-title":"How AIDS Changed Everything","author":"UNAIDS","year":"2015"},{"key":"10.1016\/j.mehy.2016.07.016_b0010","unstructured":"W.H.O. (WHO), HIV\/AIDS; 2015."},{"key":"10.1016\/j.mehy.2016.07.016_b0015","first-page":"1","article-title":"Revised surveillance case definition for HIV infection \u2013 United States, 2014","volume":"63","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.mehy.2016.07.016_b0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0030","doi-asserted-by":"crossref","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","article-title":"Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies","volume":"10","author":"Johnson","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-3542(01)00148-6","article-title":"Metabolic complications associated with antiretroviral therapy","volume":"51","author":"Jain","year":"2001","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mehy.2016.07.016_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/003655400750045196","article-title":"Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment","volume":"32","author":"Penzak","year":"2000","journal-title":"Scand J Infect Dis"},{"issue":"2005","key":"10.1016\/j.mehy.2016.07.016_b0045","first-page":"121","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.mehy.2016.07.016_b0050","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","article-title":"HIV infection and the risk of diabetes mellitus","volume":"23","author":"Butt","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.mehy.2016.07.016_b0055","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mehy.2016.07.016_b0060","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Saves","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mehy.2016.07.016_b0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1590\/S1413-86702008000400002","article-title":"Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitario Cassiano Antonio de Morais, Vitoria, ES, Brazil","volume":"1","author":"Monnerat","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.mehy.2016.07.016_b0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/0037-8682-0240-2013","article-title":"Prevalence and factors associated with lipodystrophy in AIDS patients","volume":"47","author":"Justina","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"issue":"2006","key":"10.1016\/j.mehy.2016.07.016_b0075","first-page":"590","article-title":"Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial","volume":"41","author":"Mulligan","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.mehy.2016.07.016_b0080","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/QAD.0b013e32801120e3","article-title":"Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy","volume":"20","author":"Boccara","year":"2006","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.mehy.2016.07.016_b0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1592\/phco.20.7.727.35179","article-title":"Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities","volume":"20","author":"Thomas","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"2008","key":"10.1016\/j.mehy.2016.07.016_b0090","first-page":"459","article-title":"Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186","volume":"47","author":"Gerber","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.mehy.2016.07.016_b0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/422144","article-title":"Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy","volume":"39","author":"Gerber","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2016.07.016_b0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/IJGM.S15818","article-title":"Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India","volume":"4","author":"Idiculla","year":"2011","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP1711","article-title":"Incident hyperglycaemia among older adults with or at-risk for HIV infection","volume":"16","author":"Polsky","year":"2011","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.mehy.2016.07.016_b0110","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.7448\/IAS.15.2.17426","article-title":"Predicting the short-term risk of diabetes in HIV-positive patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"15","author":"Petoumenos","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.mehy.2016.07.016_b0115","doi-asserted-by":"crossref","first-page":"e44575","DOI":"10.1371\/journal.pone.0044575","article-title":"Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study","volume":"7","author":"Rasmussen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2016.07.016_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0130","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.2174\/138161210793563527","article-title":"Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment","volume":"16","author":"Giralt","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2016.07.016_b0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/jhg.2013.107","article-title":"Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies","volume":"59","author":"Nolis","year":"2014","journal-title":"J Hum Genet"},{"key":"10.1016\/j.mehy.2016.07.016_b0140","first-page":"214","article-title":"What to do after basal insulin: 3 Tx strategies for type 2 diabetes","volume":"64","author":"Presswala","year":"2015","journal-title":"J Fam Pract"},{"key":"10.1016\/j.mehy.2016.07.016_b0145","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2016.07.016_b0150","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mehy.2016.07.016_b0155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2016.07.016_b0160","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mehy.2016.07.016_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2042018814558242","article-title":"Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","volume":"6","author":"Harris","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.mehy.2016.07.016_b0170","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mehy.2016.07.016_b0175","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.mehy.2016.07.016_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1475-2840-10-109","article-title":"Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes","volume":"10","author":"Inoue","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.mehy.2016.07.016_b0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.mehy.2016.07.016_b0190","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8227(09)70006-3","article-title":"Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide","volume":"86","author":"van Genugten","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.mehy.2016.07.016_b0195","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2008.02484.x","article-title":"Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes","volume":"25","author":"Courreges","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0016-5085(92)91090-Q","article-title":"Peptides in the gastrointestinal tract in human immunodeficiency virus infection. The GI\/HIV Study Group of the University of Calgary","volume":"103","author":"Sharkey","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2016.07.016_b0205","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1053\/j.gastro.2008.12.071","article-title":"The gastrointestinal tract and AIDS pathogenesis","volume":"136","author":"Lackner","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2016.07.016_b0210","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2016.07.016_b0215","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3892\/mmr.2013.1744","article-title":"Lipopolysaccharide-induced apoptosis in a murine intestinal endocrine cell line by modulation of Bcl-2, Bax and caspase-3","volume":"8","author":"Lei","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.mehy.2016.07.016_b0220","doi-asserted-by":"crossref","first-page":"e75967","DOI":"10.1371\/journal.pone.0075967","article-title":"Gastrointestinal viral load and enteroendocrine cell number are associated with altered survival in HIV-1 infected individuals","volume":"8","author":"van Marle","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2016.07.016_b0225","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.2337\/dc12-0021","article-title":"Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes","volume":"35","author":"Diamant","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716303954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716303954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T02:50:24Z","timestamp":1536547824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716303954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":45,"alternative-id":["S0306987716303954"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2016.07.016","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2016.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}